What is the AURA system and how does it work in IVF?

AURA is an AI-powered robotic assembly line that automates key steps in creating human embryos for IVF, using precision robots for tasks like sperm selection and fertilization.

Who developed the AURA robot for fertility treatments?

The AURA robot was developed by Conceivable Life Sciences Inc., a startup focused on using automation to improve and expand access to fertility care.

What are the ethical concerns surrounding AI in IVF like the AURA system?

Concerns include the potential for large-scale errors, the ethical implications of automating human procreation, and whether cost savings will benefit patients or clinics.

Home / Technology / Robots Build Babies: IVF Revolution Begins

Robots Build Babies: IVF Revolution Begins

9 Jan

•

Summary

An AI-powered robotic assembly line called AURA creates human embryos.
Conceivable Life Sciences aims to expand fertility access with automation.
Critics raise concerns about AI in procreation and potential errors.

Robots Build Babies: IVF Revolution Begins

In Mexico City, a novel AI-powered robotic system named AURA is making headlines for its ability to automate human embryo creation, a process previously handled solely by humans. This technology, developed by Conceivable Life Sciences, utilizes precision robots to perform critical steps in IVF, aiming to improve success rates and expand access to fertility treatments globally.

The AURA system, operating in a Mexico City clinic, performs tasks such as sperm selection and fertilization with remarkable accuracy. While the company believes this automation will democratize fertility care, critics express concerns about the potential for large-scale errors and the ethical implications of removing human involvement from procreation.

Despite the controversies, Conceivable Life Sciences has successfully piloted its technology, with one of its founders even using the system to conceive a child. The company is seeking further investment to bring its advanced, automated approach to the broader US market, positioning itself as a leader in the future of reproductive technology.